Elective laparoscopic tension-free repair of a right indirect inguinal hernia in a patient on long-term warfarin anticoagulation after mechanical mitral valve replacement: a case report
This case report demonstrates that elective laparoscopic tension-free inguinal hernia repair can be safely performed in patients with mechanical mitral valve prostheses on long-term warfarin therapy through a multidisciplinary approach utilizing guideline-based perioperative bridging anticoagulation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of people around the world undergo surgery to repair a weakness in the groin where the abdominal wall gives way, allowing tissue to bulge through. While this is a common and usually straightforward procedure, the path to the operating room becomes far more complex for patients who carry a mechanical heart valve. These artificial replacements, often made of metal or carbon, are life-saving devices that keep blood flowing correctly, but they have a dangerous side effect: the body naturally tries to clot around them. To prevent a clot from forming and blocking the valve, patients must take blood-thinning medication for the rest of their lives. This creates a difficult dilemma for surgeons. If the medication is stopped before surgery to prevent dangerous bleeding during the operation, the patient risks a clot forming on the heart valve, which can be fatal. If the medication is continued, the patient risks bleeding too much during the surgery. Finding the right balance for these patients has long been a challenge, particularly for minimally invasive techniques that are becoming the standard for hernia repair.
A team of surgeons in China recently documented the successful management of this exact dilemma in a 61-year-old man. The patient had lived with a mechanical valve in his mitral position for seven years and had been taking warfarin, a common blood thinner, to keep his blood from clotting. He arrived at the hospital with a reducible hernia in his right groin, a swelling that could be pushed back inside the abdomen. The medical team faced a critical decision: how to operate without triggering a clot on his heart valve or causing uncontrolled bleeding. They assembled a group of specialists, including heart surgeons, cardiologists, anesthesiologists, and general surgeons, to design a precise plan. Instead of simply stopping the blood thinner, they chose a strategy known as bridging. This involves swapping the long-acting oral medication for a shorter-acting injectable one that can be stopped and started quickly, acting as a temporary safety net.
The process began a week before the scheduled surgery. The patient stopped taking his daily warfarin pills, and doctors started giving him injections of a calcium-based heparin every twelve hours. This injectable medication thinned his blood just enough to protect the heart valve while allowing the doctors to stop it quickly when the time came. For six days, the team monitored his blood closely. On the day before the operation, they stopped the injections. By the time the surgery began, his blood had returned to a normal thickness, meaning it would not bleed excessively during the procedure, yet the window of time without protection was kept as short as possible to avoid clotting risks.
The operation itself was performed using a laparoscopic approach, a technique where the surgeon works through small incisions using a camera and long instruments. This method allowed the surgeon to see the inside of the abdomen clearly and place a mesh patch to reinforce the weak spot in the groin wall without making a large cut. The surgery went smoothly, with no damage to blood vessels or organs, and the surgeon confirmed that all bleeding had stopped before closing the patient up. Crucially, the team waited only one day after the operation to restart the blood-thinning regimen. They resumed the injectable heparin and the oral warfarin together, ensuring the patient was protected from clots again almost immediately.
The results were exactly what the team had hoped for. The patient did not experience any bleeding complications, such as a collection of blood under the skin or a drop in his red blood cell count. Equally important, he did not suffer any clots or strokes. At a follow-up visit one month later, the hernia had not returned, the patient felt no chronic pain, and he had returned to his normal daily activities. This case demonstrates that with a carefully coordinated plan involving multiple specialists, it is possible to safely perform elective hernia surgery on patients with mechanical heart valves. The key lies in the timing: stopping the long-term medication well in advance, using a temporary injectable substitute, and restarting protection as soon as the surgery is over. While this report focuses on a single patient, it offers a clear roadmap for how to navigate the delicate balance between preventing clots and preventing bleeding in high-risk surgical candidates.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.